We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Lung Cancer
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
Lewis Attas
Feb 07, 2022
I think 5 is the best answer . i would continue osi and add the RET inhibitor
Angela Xu
Feb 09, 2022
I choose 5. Might add some anti angiogenesis as well. Let targeted therapies do their best and last switch to chemo.
Jean-Yves Douillard
Feb 14, 2022
I would suggest to keep Osimertinib and add Selpercatinib considering the new existence of a detectable RET fusion as an additional target for which the drug has been approved. I would rather chemotherapy as long as possible.
Dec 31, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Lewis Attas
Feb 07, 2022
Angela Xu
Feb 09, 2022
Jean-Yves Douillard
Feb 14, 2022
Dec 31, 2024
Pending Moderator approval.